Matthew C Kapusta insider trades

Open-market stock purchases and sales by Matthew C Kapusta, CEO, Managing Director at uniQure NV, from SEC Form 4 filings since Feb 2, 2012.

Track record: 50% of 2 scored buys are up 5% or more since purchase, averaging -4%.

Recent trades

DateStockTradeValue
Jul 2, 2026QURE uniQure NVSold$409K
Jul 2, 2026QURE uniQure NVSold$195K
Jul 2, 2026QURE uniQure NVSold$349K
Jul 2, 2026QURE uniQure NVBought (not open market)$409K
Jul 2, 2026QURE uniQure NVBought (not open market)—
Jun 25, 2026QURE uniQure NVSold$1.4M
Jun 25, 2026QURE uniQure NVBought (not open market)—
Jun 24, 2026QURE uniQure NVSold$335K
Jun 24, 2026QURE uniQure NVBought (not open market)—
Jun 18, 2026QURE uniQure NVSold$233K
Jun 18, 2026QURE uniQure NVSold$1.9M
Jun 18, 2026QURE uniQure NVBought (not open market)—
Jun 17, 2026QURE uniQure NVSold$1M
Jun 17, 2026QURE uniQure NVSold$263K
Jun 17, 2026QURE uniQure NVSold$1.5M
Jun 17, 2026QURE uniQure NVSold$2.5M
Jun 17, 2026QURE uniQure NVSold$1.5M
Jun 17, 2026QURE uniQure NVSold$564K
Jun 17, 2026QURE uniQure NVBought (not open market)—
Mar 4, 2026QURE uniQure NVBought (not open market)—
Mar 4, 2026QURE uniQure NVSold$132K
Mar 4, 2026QURE uniQure NVBought (not open market)—
Mar 2, 2026QURE uniQure NVSold$343K
Feb 25, 2026QURE uniQure NVSold$295K

Companies traded

  • QURE uniQure NV: 130 sales, last Jul 2, 2026
  • DBTX Decibel Therapeutics, Inc: other filings, last Sep 25, 2023
  • ANGO Angiodynamics Inc: 2 buys, last Nov 17, 2014

Get free alerts when Matthew C Kapusta files a new trade →